Asset
PRASINEZUMAB
Prothena Corporation plc Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02157714 | phase1 | completed | 2014-06-01 | 2016-09-01 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease |
| NCT02095171 | phase1 | completed | 2014-03-01 | 2014-12-01 | Prothena Biosciences Limited | Single Ascending Dose Study of PRX002 in Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.